CTNM vs TRVI
CTNM: A clinical-stage biopharmaceutical company developing small-molecule therapies targeting neuroimmune and inflammatory indications, with lead programs PIPE-791 for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307 for depression and multiple sclerosis. TRVI: Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated with severe lung diseases like IPF.
Side-by-side fundamentals
| Metric | CTNM | TRVI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $14.73 | $17.36 | |
| Market cap as of 2026-07-23 | $518M | $2.5B | |
| PEG as of 2026-07-23 | -6.25 | n/a | |
| Net margin as of 2026-07-23 | +45.4% | n/a | |
| Operating margin as of 2026-07-23 | +32.1% | n/a | |
| ROE as of 2026-07-23 | -27.1% | -24.5% | TRVI higher |
| ROA as of 2026-07-23 | -25.6% | -23.4% | TRVI higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 0.62 | 1.02 | |
| 1-year return as of 2026-07-22 close | +146.0% | +166.6% | TRVI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.